Moreover, tumour shrinkage with targeted therapies may be delayed or absent, even if the drug is biologically efficient and some tyrosine-kinase inhibitors have been shown to provide patient benefit even after RECIST-defined progression, such as EGFR inhibitors in non-small cell lung cancer [33]. This evidence concerns the gene EGFR and neoplasm.